A study published in Rheumatology & Autoimmunity challenges the assumption that achieving clinical remission in rheumatoid arthritis is sufficient, showing that patient-reported outcomes vary significantly by drug class even when disease activity is comparable.
Investigators found that patients taking TNF inhibitors reported better energy levels, mood, and emotional wellbeing than those taking older conventional drugs, while IL-6 and JAK inhibitors showed particular advantages for patients’ physical functioning. These differences persisted even after accounting for how well the underlying inflammation was controlled.
The study provides real-world evidence that different drug classes offer distinct advantages across quality-of-life domains, supporting a more nuanced, patient-centered approach to treatment selection rather than a one-size-fits-all strategy.
“Despite achieving clinical remission, patients with rheumatoid arthritis may still experience symptoms such as fatigue, sleep disturbances, and mental or communication issues compared with healthy individuals, highlighting the importance of evaluating patient-reported outcomes as a composite measure of treatment efficacy,” the authors wrote.
They noted that the study arrives at a moment when regulators are pushing for patient-reported outcomes to be formally incorporated into drug approvals and reimbursement decisions, and when artificial intelligence–based tools are beginning to use multiple data streams to match the right drug to the right patient.
URL upon publication: https://onlinelibrary.wiley.com/doi/10.1002/rai2.70048
Additional Information
NOTE: The information contained in this release is protected by copyright. Please include journal attribution in all coverage. For more information or to obtain a PDF of any study, please contact: Sara Henning-Stout, newsroom@wiley.com .
About the Journal
Rheumatology & Autoimmunity journal publishes work spanning basic, clinical and translational medical advancements across the full spectrum of rheumatology and autoimmunity.
About Wiley
Wiley is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com . Follow us on Facebook , X , LinkedIn and Instagram .
Rheumatology & Autoimmunity
Impact of biological/targeted versus conventional synthetic disease-modifying antirheumatic drugs on patient-reported outcomes in rheumatoid arthritis
22-Apr-2026